Lexicon Pharmaceuticals, Inc. (LXRX)
$
1.24
-0.07 (-5.65%)
Key metrics
Financial statements
Free cash flow per share
-0.2826
Market cap
481.5 Million
Price to sales ratio
8.2404
Debt to equity
0.4747
Current ratio
4.1648
Income quality
0.8448
Average inventory
184.5 Thousand
ROE
-0.8363
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Lexicon Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of pharmaceutical products, having achieved a revenue of $31,081,000.00 indicating its niche market focus. The cost of revenue for the company is $616,000.00 showcasing its production and operational expenses. The company’s stock is identified with the symbol 'LXRX' in the market, and its gross profit ratio stands at 0.98 reflecting the efficiency of the company's production and sales operations. Furthermore, the operating income ratio is -6.34 indicating the company's operational profitability margin. The company is engaged in the development of orally-delivered small molecule drug candidates, including Sotagliflozin, which has successfully completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, as well as LX9211, currently in Phase II clinical development for neuropathic pain management. Lexicon also maintains strategic collaborations and license agreements with Bristol-Myers Squibb Company and Genentech, Inc., enhancing its market presence. Founded in 1995, the company is headquartered in The Woodlands, Texas. In the investment landscape, the stock is affordable at $1.19 making it suitable for budget-conscious investors. Additionally, the stock exhibits a high average trading volume of 2,302,182.00 indicating strong liquidity. With a market capitalization of $448,797,592.00 the company is classified as a small-cap player within the biopharmaceutical sector. Lexicon Pharmaceuticals, Inc. is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its field. Through its robust pipeline and strategic partnerships, Lexicon continues to strive toward enhancing healthcare outcomes while providing investors with potential opportunities for growth in a rapidly evolving market.
Is Lexicon Pharmaceuticals, Inc. (LXRX) a good investment?
Investing in Lexicon Pharmaceuticals, Inc. (LXRX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Lexicon Pharmaceuticals, Inc. (LXRX)'s stock forecast?
Analysts predict Lexicon Pharmaceuticals, Inc. stock to fluctuate between $0.28 (low) and $1.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Lexicon Pharmaceuticals, Inc.'s market capitalization?
As of 2025-12-15, Lexicon Pharmaceuticals, Inc.'s market cap is $448,797,592, based on 363,398,860 outstanding shares.
How does Lexicon Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Lexicon Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Lexicon Pharmaceuticals, Inc. (LXRX) stock?
To buy Lexicon Pharmaceuticals, Inc. (LXRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LXRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Lexicon Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Lexicon Pharmaceuticals, Inc. stock ever split?
Lexicon Pharmaceuticals, Inc.'s last stock split was 1:7 on 2015-05-21.
How did Lexicon Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $31,081,000 | EPS: -$0.63 | Growth: -21.25%.
Where can I find Lexicon Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.lexpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Lexicon Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Lexicon Pharmaceuticals, Inc. stock?
All-time high: $6.33 (2021-10-15) | All-time low: $0.28 (2025-03-03).
What are the key trends affecting Lexicon Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the Journal of the Endocrine Society.
globenewswire.com
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C.
globenewswire.com
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET.
seekingalpha.com
Lexicon Pharmaceuticals, Inc. ( LXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Thank you, everyone, for tuning in. I'm Andrew Tsai, Senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today.
seekingalpha.com
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval in Type 1 diabetes and hypertrophic cardiomyopathy, but new data and ongoing trials offer near-term catalysts. Novo Nordisk partnership on LX9851 and improved pilavapadin data provide financial support and partnership credibility, helping LXRX regain Nasdaq compliance.
globenewswire.com
THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m.
globenewswire.com
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sotagliflozin treatment in heart failure patients with preserved ejection fraction (HFpEF), and without diabetes, across a range of measures, including cardiac structure and function, quality of life and functional capacity.
seekingalpha.com
Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate Communications Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Scott Coiante - Senior VP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Lexicon Pharmaceuticals Third Quarter 2025 Financial Results Conference Call.
zacks.com
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
globenewswire.com
FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corporate milestones and accomplishments. “Lexicon ushered in 2025 with an ambitious slate of objectives embracing and driving our renewed R&D focus,” said Mike Exton, Ph.D.
See all news
